Argireline
Also known as: Acetyl Hexapeptide-8, Acetyl Hexapeptide-8 Amide, Acetyl Hexapeptide-3
Argireline is a cosmetic acetyl hexapeptide with small human anti-wrinkle studies. Formulation, skin delivery and active-peptide concentration matter; it is not established as equivalent to injected botulinum toxin.
Quick Facts
What Is Argireline (Acetyl Hexapeptide-8)?
Argireline is a synthetic cosmetic hexapeptide. The 2025 safety assessment identifies Acetyl Hexapeptide-8 Amide/Acetyl Hexapeptide-8 and notes that Acetyl Hexapeptide-3 is a retired dictionary synonym, retained here for legacy searches.
The original development paper reported laboratory activity and a small topical wrinkle study. Its research rationale does not establish equivalence to an approved injected drug.
How Does Argireline Work?
The original laboratory work investigated interference with the SNARE machinery involved in neurotransmitter release, rather than simply occupying acetylcholine receptors.
An original skin-penetration experiment found most applied peptide was removed from the surface and no peptide was detected in dermis or receptor fluid in its tested human/guinea-pig skin system. This limits assumptions about delivery; it is not proof of zero absorption from every formulation.
Research & Clinical Evidence
| Research context | Existing findings, population and limits |
|---|---|
| Four-week placebo comparison | A 60-person randomized placebo comparison applied treatment twice daily for four weeks. It reported a 48.9% subjective anti-wrinkle response versus 0% with placebo and favorable objective roughness measurements. That percentage describes its subjective efficacy assessment, not a 48.9% reduction in wrinkle depth. |
| 2002 topical report | The 2002 report also described favorable skin-topography findings after 30 days. Neither study establishes equivalence to botulinum toxin, prevention of future wrinkles or a universal long-term response. |
Potential Benefits
The four-week trial supports a possible improvement in the appearance of peri-orbital wrinkles with its formulation. That is a useful cosmetic finding.
It does not establish superior results from combining Argireline with Matrixyl or replacing an injection procedure. Botox Cosmetic’s label describes an intended localized reduction in muscle activity after injection; distant spread is a safety concern, not its intended systemic mode of cosmetic action.
Usage & Application
A commercial ingredient solution’s percentage is different from its active peptide content. The 2025 assessment describes a 0.05% aqueous stock mixture; incorporating 10% of that stock would yield 0.005% active peptide, not 10% pure peptide.
The clinical comparison used a finished topical treatment. Its results do not prove a universal concentration threshold, maximum response at 8–12 weeks or superiority of higher pure-peptide concentrations.
Side Effects & Safety Profile
The 2025 expert panel concluded safety for the described cosmetic practices up to 0.005% active ingredient; above that, available data were insufficient. This is a concentration-bounded assessment, not proof of indefinite safety at any strength.
Small topical trials and a particular penetration experiment cannot establish compatibility with every skin type or absence of all systemic effects. Pregnancy, combinations and novel delivery systems require their own evidence.
Source Review and Evidence Limits
The original development, randomized wrinkle and penetration abstracts were read. The published 2025 panel report’s identity, composition, penetration and conclusion sections were read through the journal page; not all sections or underlying study full texts were obtained. These sources do not establish a current complete FDA product adjudication, clinician sign-off or certification of related guides.
Frequently Asked Questions About Argireline
Argireline is a topical cosmetic peptide; Botox Cosmetic is an injected drug with intended localized muscle effects. Their clinical evidence, delivery and dosing differ, and topical equivalence has not been established.
The cited randomized comparison assessed results after four weeks, and the original development report after 30 days. A universal rapid onset, 8–12-week peak or fixed reversal time is not established.
Complementary marketing mechanisms do not establish clinical synergy or universal compatibility. The reviewed trials do not demonstrate that the combination outperforms either ingredient alone.
The reviewed evidence does not establish equal efficacy to Botox Cosmetic. A favorable small topical wrinkle study is not a head-to-head drug-equivalence trial.
The 2025 expert-panel conclusion is bounded to described cosmetic use up to 0.005% active; evidence above that was insufficient. It is not a guarantee for every finished formulation or indefinite use at any concentration.
Related Peptides
Continue exploring Argireline
Search all related references →Our library review is ongoing. Read how we evaluate evidence or report a correction.
Disclaimer: This article is for informational and educational purposes only. It is not intended as medical advice. The information presented is based on published research and should not be used as a substitute for professional medical guidance. Always consult a qualified healthcare provider before starting any peptide protocol. Some peptides discussed may not be approved for human use by the FDA or equivalent regulatory bodies.